Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMAGEWARE SYSTEMS INCIWSY · Entity 125373 | PRESIDENT & CEO | April 16, 2021 | April 21, 2021 |
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director | September 30, 2022 | October 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMAGEWARE SYSTEMS INC
Report date April 16, 2021 · Filed April 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2031-04-16 | Direct | 27,000,000 |
Reported balance
After 2021-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-16 · Grant · Acquired 27,000,000 · Balance 27,000,000 F1: 1/10th of the stock options vest on the date of the grant, 1/3rd of the remaining unvested stock options vest on February 28, 2022, and the remainder vest in equal monthly installments over the following 24 month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/10th of the stock options vest on the date of the grant, 1/3rd of the remaining unvested stock options vest on February 28, 2022, and the remainder vest in equal monthly installments over the following 24 month period thereafter.
PURE BIOSCIENCE, INC.
Report date September 30, 2022 · Filed October 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2032-09-30 | Direct | 125,000 |
Reported balance
After 2022-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-30 · Grant · Acquired 125,000 · Balance 125,000 F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2022 Filed Oct 4, 2022 20:32 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001209191-22-052242 · doc4.xml · derivative · entry 1 Taylor Kristin · CIK 0001809801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-09-30 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024. Read SEC document |
| June 18, 2021 Filed Jun 23, 2021 00:26 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-21-042596 · doc4.xml · derivative · entry 1 Taylor Kristin · CIK 0001809801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 14:01 UTC | IMAGEWARE SYSTEMS INC IWSY · Entity 125373 | GrantStock Options · Derivative | 27,000,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001415889-21-002047 · form4-04212021_110402.xml · derivative · entry 1 Taylor Kristin · CIK 0001809801 · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000,000 Underlying: Common Stock · 27,000,000 shares Expires 2031-04-16 F1 · derivative.exercise_date: 1/10th of the stock options vest on the date of the grant, 1/3rd of the remaining unvested stock options vest on February 28, 2022, and the remainder vest in equal monthly installments over the following 24 month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.